Several studies have reported that the combination of chemotherapy and anti-PD-1/PD-L1 treatment for metastatic NSCLC as a first-line therapy significantly improves the treatment response, OS, and PFS of patients (24–27). The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.